GLAUKOS CorpGKOS

時価総額

$64.2億

PER

眼科向け治療薬・医療機器の大手。iStentファミリーやiDose TRなどのMIGS製品と角膜治療薬を展開、従業員約995人（2024年12月31日時点）の体制。2012年のiStent商業化以降成長を遂げ、2024年3月に臨床段階バイオ企業を買収、同年12月に転換社債を償還したイベント。米国中心で売上の70%を占める展開地域。

概要財務

サマリーテーブルに戻る

	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-38	5	-0	-13	15	-120	-50	-99	-135	-146
Depreciation	-	-	-	-	-	-	-	7	9	11
Amortization of intangible assets	-	-	-	-	-	-	-	25	25	25
Amortization of right-of-use lease assets	-	-	-	-	-	-	5	4	4	4
Amortization Of Financing Cost	-	-	-	-	-	-	1	1	1	1
Deferred income tax benefit	-	-	-	-	-66	-12	-1	-0	-0	-0
Loss (gain) on disposal of fixed assets	-	-0	-0	-0	-0	-0	-0	0	-1	-1
Stock-based compensation	8	9	18	26	36	46	30	39	44	50
Unrealized foreign currency losses (gains)	-	-0	1	-2	-0	1	-2	-2	1	-5
Amortization of Discount on Short Term Investments	-	-	-	-	-	0	1	1	-2	-4
Other liabilities	-	-	-	-	-	-	2	1	3	5
Acquired in-process R&D acquired through the issuance of common stock	-	-	-	-	-	-	-	-	3	5
Loss on capped call transaction	-	-	-	-	-	-	-	-	-	1
Inducement expense related to exchange of convertible senior notes	-	-	-	-	-	-	-	-	-	17
Inventory write-down	-	-	-	-	-	-	-	-	-	4
Accounts receivable, net	2	7	2	2	7	-2	-2	3	4	22
Inventory	2	3	4	2	-4	-2	8	15	5	19
Prepaid expenses and other current assets	1	-2	0	-2	-1	-5	-3	-2	-1	3
Accounts payable and accrued liabilities	2	5	10	3	1	-3	12	7	1	0
Other assets	0	-0	1	-0	2	-0	-0	0	2	2
Net cash used in operating activities	-	-	26	19	-0	-23	25	-33	-58	-61
Purchases of property and equipment	1	6	6	10	5	7	48	30	20	6
Purchases of short-term investments	70	75	94	94	80	301	215	59	266	190
Proceeds from Sale and Maturity of Marketable Securities	-	55	89	79	80	105	207	135	303	247
Proceeds from disposal of property and equipment	-	-	-	-	-	-	0	0	-	0
Investment in company-owned life insurance	-	-	-	1	2	2	2	1	3	3
Net cash provided by investing activities	-	-	-12	-26	43	-205	-58	45	14	48
Proceeds from Convertible Debt	-	-	-	-	-	-10	-	-	-	53
Proceeds from Stock Options Exercised	2	6	4	19	15	20	26	4	13	39
Share purchases under Employee Stock Purchase Plan	1	2	1	4	3	4	5	6	6	7
Payments of employee taxes related to vested restricted stock units	-	-	-	1	6	4	4	3	3	7
Payments related to convertible senior notes	-	-	-	-	-	-	-	-	-	1
Payments related to capped call transactions	-	-	-	-	-	-	-	-	-	0
Principal paid on finance lease	-	-	-	-	-	-	1	1	1	1
Net cash provided by financing activities	-	-	5	22	-10	263	39	6	15	92
Effect of exchange rate changes on cash and cash equivalents	-	-	-	-	-	-	-	-1	1	-3
Net increase (decrease) in cash, cash equivalents and restricted cash	-	-	-	14	33	34	4	16	-27	75
Capital Expenditures Incurred but Not yet Paid	-	-	-	-	1	1	2	4	1	1
Debt Conversion, Converted Instrument, Amount	-	-	-	-	-	-	-	-	-	227
Stock Issued	-	-	-	-	-	-	-	-	-	57
Income Taxes Paid, Net	-	-	0	0	0	0	0	1	2	1
Interest paid on convertible senior notes	-	-	-	-	-	4	8	8	8	5
Other interest paid	-	-	-	-	0	1	4	4	4	4